Navigation Links
Merging discovery with therapy: Second generation memory care debuts
Date:2/19/2008

INDIANAPOLIS -- Researchers and clinicians from the Indiana University School of Medicine and the Regenstrief Institute are blurring the distinction between lab and clinic as they debut the second generation of memory care.

Building upon a care model they developed and extensively tested over the past 7 years, the focus of second generation memory care is on two groups -- patients with cognitive disorders such as Alzheimer's disease and their caregivers. Results of the clinical trial of the IU-Regenstrief care model were published in the Journal of the American Medical Association in 2006.

The initial second generation memory center -- the Healthy Aging Brain Center opens at the IU Center for Senior Health at Wishard Health Services this month.

"When we make the lab from which we develop treatments and the clinic into one entity, we are constantly learning from our patients -- what works for them and what does not. Our approach to memory care is on the fast track because by eliminating the distinction between the lab and the clinic, we compress the long timeline traditionally needed to go from discovery to treatment. For us and for those we treat, who are both those with memory problems and their caregivers, this means that they will be receiving the support and care they need now," said Malaz Boustani, M.D., M.P.H., an assistant professor of medicine at Indiana University School of Medicine, an Indiana University Center for Aging Research investigator and a Regenstrief Institute research scientist.

Dr. Boustani is also the chief research officer of the Indianapolis Discovery Network for Dementia, an expanding group of researchers, clinicians, caregivers and community advocates who are working to enhance dementia care in the nation's twelfth largest city. IDND is a national model for how members of the community, caregivers, clinicians and researchers can work together to improve the delivery of dementia care. Second genera
'/>"/>

Contact: Cindy Fox Aisen
caisen@iupui.edu
317-274-7722
Indiana University
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. New findings on emerging contaminants
2. 2008 International Conference on Emerging Infectious Diseases
3. 2008 ASM Biodefense and Emerging Disease Research Meeting
4. An emerging candidate for protecting patients from liver injury after abdomen surgery
5. Abaxis, Inc. to Present at the Fifth Annual Sidoti & Company Emerging Growth Conference
6. QED International Associates Announces Changes to the HealthShares(TM) Emerging Cancer Index
7. OneMedPlace Emerging Healthcare Technologies Finance Forum Jan 7, 8th
8. Food and Drug Law Institute, Project on Emerging Nanotechnologies Co-Sponsor Major Conference on Nanotechnology Law, Regulation and Policy
9. Emerging therapies with a focus on Asian populations mark the AACR Centennial Conference
10. Targets on the horizon: Emerging therapies and novel targets
11. HealthShares(TM) Announces Change to the HealthShares(TM) Emerging Cancer Index

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...urn causes demand for affordable drug and alcohol ...a sharp increase in demand for its services and at...s led to an increase in alcoholic binge drinking, ... (PRWEB) December 3, 2009 -- Mountainside... spike in demand for its services due to the econo...
(Date:12/3/2009)...Newswire-USNewswire/ -- The American Association f...from one of the largest studies to date on passive...he Northern California Cancer Center (NCCC) . ,...ed cigarettes and who were exposed to secondhand c...adulthood--had a significantly increased breast ca...
(Date:12/3/2009)...3 For California,s 3.4 million own... remains one of the most significant threats to no...so their business,s viability. ,, "As the rece...wners of small businesses are recognizing the need...ced disability coverage," said Michael Hagedorn, ...
(Date:12/3/2009)...RNewswire/ -- Southern Tier HealthLink NY (STHL) h...a global leader in eHealth technology, to provide ...alth Information Exchange (HIE). ICW will impleme...erprise Master Provider Registry (EMPR) and Integr...sidents, 8 hospitals, and over 800 physicians in c...
(Date:12/3/2009)... the livers of primates , , , THURSDAY,...patitis C has shown promise in a primate study. ,...o prevent the hepatitis C virus from replicating. ...lf, the new DNA-based drug targets a small RNA mol...cate, the researchers explained. , By inhibitin...
Breaking Medicine News(10 mins):Health News:Economic Crisis Causes Acute Demand for Affordable Drug Addiction Treatment 2Health News:Northern California Cancer Center's Findings on Breast Cancer and Secondhand Smoke Released Internationally by the American Association for Cancer Research 2Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 2Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 3Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 4Health News:Southern Tier HealthLink NY Selects InterComponentWare to Deliver Core Components of HIE 2Health News:New Hepatitis C Treatment Shows Promise 2Health News:New Hepatitis C Treatment Shows Promise 3
...that detects and treats cancer cells that are resi...iation showed success in the laboratory and could ...ccording to researchers at SNM,s 55th Annual Meeti...s them unresponsive to most current treatments. , ...
...he SNM 55th Annual Meeting, shows that radioimmuno...vel option to treator even preventmany viral cance...gens or infected cells before they convert into ma...fessor of nuclear medicine and microbiology and im...
...nd red wine, reduces the number of fat cells and m...cording to a new study. The results will be presen... in San Francisco. , Past research found that re...tion. Researchers at the University of Ulm in Germ...
...,WBMD) and HLTH Corporation (Nasdaq: HLTH ) today...to participate at the William Blair 28th Annual,Gr...at 1:30 p.m. ET., Investors, analysts and the gen...om (in the Investor Relations section). A,replay ...
.... (LPI),announced today that it has received tenta...ug Application (ANDA) for Escitalopram Oxalate Tab...dministration (USFDA)., Lupin,s Escitalopram tabl...d product had annual sales of,approximately $2.6 b...
...nth finds that hospitals that perform well on the ...better quality of care than those who,either didn,...o complete,the survey. The study was published in ...ns and,individuals who pay for health care know th...
Other Medicine News:Health News:New therapy shows promise for fighting treatment-resistant cancer cells 2Health News:New study shows potential to treat or prevent viral cancers 2Health News:Red wine's resveratrol may help battle obesity 2Health News:WebMD to Present at the William Blair 28th Annual Growth Stock Conference 2Health News:Lupin Receives USFDA Approval for Escitalopram Oxalate Tablets 2Health News:Harvard Study in Joint Commission Journal: Mortality Rates Lower in Leapfrog Hospitals 2Health News:Harvard Study in Joint Commission Journal: Mortality Rates Lower in Leapfrog Hospitals 3
(Date:12/3/2009)...DFORD, Mass., Dec. 3 MicroCHIPS, a...ems, today announced it has been named a 2010 Tech..., The company was selected for pioneering a novel ...sive implants designed to bridge the gap between d...nologies have broad applicability, from ,rescue, a...
(Date:12/3/2009)..., MAPLE GROVE, Minn., Dec. 3 Upshe...t phase of its strategic plan for central nervous ...e topiramate), an internally developed program for...oped with Upsher-Smith,s proprietary formulation t...l in early 2010 for the adjunctive treatment of ep...
(Date:12/3/2009)...N DIEGO, Dec. 3 Amira Pharmaceut...from a Phase 1 clinical study of AM461, the Compan...lso known as CRTH2) receptor. ,, The interim ...acodynamic (PD) effect can be achieved with AM461....rates a good safety profile. AM461 is a back-up t...
Breaking Medicine Technology:MicroCHIPS Named 2010 Technology Pioneer by World Economic Forum 2Upsher-Smith Announces Milestone in Development of CNS Strategy 2Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amira's Lead DP2 Antagonist, AM211 2United States Navy And Merchant Marine Veterans May Face Risk Of Mesothelioma Or Other Asbestos Diseases 60212 1United States Navy And Merchant Marine Veterans May Face Risk Of Mesothelioma Or Other Asbestos Diseases 60212 2United States Navy And Merchant Marine Veterans May Face Risk Of Mesothelioma Or Other Asbestos Diseases 60212 3United States Navy And Merchant Marine Veterans May Face Risk Of Mesothelioma Or Other Asbestos Diseases 60212 4New York Merchants Protective Co Designated as Authorized Geutebruck Solutions Provider 60207 1New York Merchants Protective Co Designated as Authorized Geutebruck Solutions Provider 60207 2New York Merchants Protective Co Designated as Authorized Geutebruck Solutions Provider 60207 3Central Blood Bank Offers Twilight Fans a way to be Among First to see the Highly Anticipated Sequel New Moon 60202 1Central Blood Bank Offers Twilight Fans a way to be Among First to see the Highly Anticipated Sequel New Moon 60202 2Central Blood Bank Offers Twilight Fans a way to be Among First to see the Highly Anticipated Sequel New Moon 60202 3
...ike a radio dial, not an on/off,light switch; a di...evelop,late in life, MEMPHIS, Tenn., May 12 A St...at T cells, the body,s master immune,regulators, d...lular,machinery that regulates their development a...lecular controls that enable them to adjust their,...
...ms, Inc.,(OTC Bulletin Board: ABOS) announced toda...U.S. Food and Drug Administration ("FDA") of an,In...e pivotal clinical,trial for SEPET(TM), Arbios, ex...e for blood purification of acutely ill patients s...ased to have received FDA approval to start the SE...
Other Medicine Technology:St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 2St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 3St. Jude Study Shows How T Cell's Machinery Dials Down Autoimmunity 4Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 2Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 3Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 4Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device 5
...lar is the first HbA1c control available with inta...edure including the lysing of the red blood cell. ...an open-vial stability of 30 days and a closed-via...ellular is appropriate for immunoassay and ionic e...
Siemens Video: Heart of a Soldier
Siemens Webcast: Soarian Disease Management
Siemens Webcast: Legislative Developments Impacting Cardiology Services Reimbursement
Medicine Products: